13th Nov 2026 08:37
(Alliance News) - GSK PLC on Friday said an EU advisory panel has recommended the use of Bexsero as a booster for older children who previously received the vaccine against Meningitis B.
The London-based pharmaceuticals maker said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the label of its Bexsero meningitis B vaccine to include a single booster dose for people aged 10 and older who received their initial vaccination at least two years earlier.
The recommendation was supported by data from a phase IIIb trial involving 312 participants, which met its primary endpoint and showed that immune memory established through vaccination in infancy can be boosted up to 19 years later, GSK said.
The booster could help maintain protection into adolescence, when meningococcal disease incidence reaches a second peak, the company explained. Invasive meningococcal disease can progress rapidly and may result in death or long-term complications.
"As the first generation of children vaccinated against MenB in infancy reaches adolescence, today's positive CHMP opinion supports maintaining protection with a single booster dose during a second period in life of increased disease risk," said Sanjay Gurunathan, senior vice president for R&D Vaccines & Infectious Diseases at GSK.
Bexsero is currently registered in 61 countries, with around 140 million doses distributed globally since 2015.
GSK shares were up 0.4% to 1,908.00 pence early Friday in London.
By Tom Waite, Alliance News editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline